

Adaptive Immunity

Cellular Mechanisms and Signaling

Olivera (Olja) Finn, PhD

University of Pittsburgh School of Medicine

University of Pittsburgh Cancer Institute

Defense reactions

- **Recognition of a threat**
 - Signaling molecules and signal receptors on innate immune cells
 - Antigen receptors and signaling molecules on adaptive immune cells
- **Processing**
 - Analysis of the received signal
 - Threshold
- **Response (effector phase)**
 - Propagation of the danger message
 - Elimination of the threat

Two types of immunity

- **Innate immunity**


- Stimulated by pathogens, signal to adaptive immunity
- *Immediate response*
- *Broad reactivity*
- Players:
 - Epithelial barriers (skin, mucosa)
 - Complement system
 - NK cells
 - Phagocytes (DC and MØ)

- **Adaptive Immunity**

- Stimulated by pathogen-derived antigens, and by innate immunity
- *Delayed response*
- *Narrow specificity*
- *Two types: humoral and cellular*
- Players:
 - B cells (antibodies)
 - T cells (CTL and Th)
 - NKT cells

A perfectly orchestrated and timed system

Pittsburgh Symphony Orchestra



Discovery of Humoral Immunity (Antibodies)

- Alexandre Yersin and *Corynebacterium diphtheria* toxin (1888).
 - Observed that bacteria localized only in the throat but lesions seen throughout the body
 - Cell free filtrates made mice sick (*toxins*)
- Emil von Behring Serum from mice that recovered could transfer resistance to previously uninfected mice.
 - Mice that recovered were resistant to disease
 - Serum from mice that recovered could transfer resistance to previously uninfected mice (*antitoxins*).



The Nobel Prize in Physiology or Medicine 1901 was awarded to Emil von Behring "for his work on serum therapy, especially its application against diphtheria, by which he has opened a new road in the domain of medical science and thereby placed in the hands of the physician a victorious weapon against illness and deaths".

Humoral Immunity

- In 1897 Rudolph Kraus discovered that immune serum precipitated the toxins (*precipitins*) and lysed the bacteria (*bacteriolysins*).
- Immune serum also glued bacteria together (*agglutinins*)
- 1923, Heidelberger and Avery discover that immune serum can recognize proteins or carbohydrates.
- In 1930, Karl Landsteiner ascribed all these different functions to the same family of molecules, *antibodies*.

1930 Nobel Prize in medicine



Karl Landsteiner (1868-1943)

Antibodies

- Can be generated not only against bacteria but also against non-bacterial and totally innocuous substances (milk, eggwhite)
- Substances stimulating the appearance of antibodies were designated *antigens*



Gerald Edelman and Rodney Porter (1972)

The two scientists independently deciphered the structure of antibodies, which revealed how seemingly identical-looking molecules can target specifically any one of a countless number of invaders for destruction.

Secreted form of IgG, 2 heavy chains and 2 light chains, held together by S-S bonds





Figure 3-1 part 1 of 3 Immunobiology 6/e (© Garland Science 2005)



The Fab vs Fc

- Fab
 - Fragment that antigen binds, V regions
 - Composed of Light chain + NH₂ portion of H chain
- Fc
 - Heavy chain Constant regions, no light chain
 - COOH end of H chain
 - Complement binding region
 - Interacts with Fc receptors



**1984 Nobel
Prize:
Niels Jerne
George
Kohler
Cesar
Milstein**

Antibodies

- Can be generated not only against bacteria but also against non-bacterial and totally innocuous substances (milk, eggwhite)
- Substances stimulating the appearance of antibodies were designated *antigens*
- **Diversity** and **Specificity** are observed but mechanisms remain a mystery until the late 1970s


100-year old puzzle solved




Susumu Tonegawa

1987 Nobel Prize for
discovering Ig gene
rearrangement

V(D)J region Sequences arise from DNA recombination









Key concepts


- Different choices of which V, D or J (heavy) or V:J (light) segments are recombined and made in individual B-cells.
- Productive rearrangements occur only on one chromosome (allelic exclusion).
- Each of these rearrangements and combinations has a different primary amino acid sequence.
- Each B cell thus would thus carries a different BCR with different antigen binding capabilities (idiotypes).



Where this all happens




B cells need T cells (and everyone needs DC)









TCR loci alpha and beta chain rearrangements




Figure 5.3 The Immune System, 3ed. (© Garland Science 2009)

BCR vs TCR








Figure 3.1 The Immune System, 3ed. (© Garland Science 2009)

Trans
membrane
region
missing in
secreted Ig

Antibody molecules only recognize a part of a large antigen, the epitope




Contrast between B cell antigen recognition and T cell's need for MHC



The interaction between the TCR (yellow and salmon) the pMHC I (green and cyan)

Each (TCR/ MHC + antigenic peptide) is attached to a cell membrane
TCR shows MHC restriction



1980 Nobel Prize



Jean Dausset




Baruj Benaceraff



George Snell

**Nobel Prize in 1996 for
“discovering the nature of the cellular immune
defense”**






Dr. Pamela Bjorkman




Don Wiley, 1944-2002

A picture is worth a thousand experiments


(a) **Class I MHC**




(b) **Class II MHC**





Between 1985-1995







Signaling through BCR




T cell recognition of antigen







CTLA-4 is an inhibitory receptor that down-regulates T-cell activation when bound to B7 proteins on antigen-presenting cells.




PD-1 is an inhibitory receptor that down-regulates T-cell activation when bound to a PD-L1 or PD-L2 ligand on tumor cells.



BCR signaling and downstream pathways.





APC

CD155 CD112 Ceacam-1 ICOSL CD40 OX40L Tim-1 Tim-4 PD-1L


T cell

CD226 TIGIT Tim-3 ICOS CD40L OX40 Tim-1 PD-1 PROCR PAR1 CD5L


Th1 Th17 Th2 TFH Th17 pathogenicity

Th2 Th1 Th17 Th2 Th1 TFH


MHC Class II restricted CD4 T helper cell subsets





MHC Class I restricted CD8 T cells




CD8 T cells need CD4 T cell help








Primary vs secondary (memory) response



Summary: Adaptive Immunity

- Antigen specific and antigen driven
- Dependent on and jump-started by innate immunity
- Cellular effectors (T cells and B cells) and their soluble effectors responsible for disease elimination
- Cellular effectors directed to long term memory responsible for prevention of disease recurrence

Innate and adaptive immune symphony in tumor immunosurveillance



Recommended reading

- Malissen B and Bongrand P. Early T cell activation: integrating biochemical, structural and biophysical cues. *Annu. Rev. Immunol.* 2015. 33:539-61
- Huang W and August A. The signaling symphony: T cell receptor tunes cytokine-mediated T cell differentiation
- Muller SN and Mackay LK. Tissue resident memory T cells: specialist in immune defence. *Nature Rev Immunol.* 2015. 15:731-44
- Amsen D, van Gisbergen KPJM, Hombrink P, van Lier RAW. Tissue resident memory T cells at the center of immunity to solid tumors. *Nature Immunol* 2018. 19:538-546
- Ghosen E, Yoshimoto m, Nakauchi H, Weissman IL, Herzenberg LA. Hematopoietic stem cell-independent hematopoiesis and the origins of innate-like B lymphocytes. *Development* 2019. 146:
- Levin Y, Mortha A, Rahman A, merad M. Regulation of macrophage development and function in peripheral tissues. *J Leukoc. Biol.* 2015. 97: 477-485